Molecular Partners shares are trading higher after the company announced its radio-DARPin therapy candidate MP0712 was supported by in vivo data presented at the European Association of Nuclear Medicine Congress. The first-in-human start and initial clinical data are expected in 2025.
Portfolio Pulse from Benzinga Newsdesk
Molecular Partners shares rose following the announcement of positive in vivo data for their radio-DARPin therapy candidate MP0712, presented at the European Association of Nuclear Medicine Congress. Initial clinical data is anticipated in 2025.
November 01, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Molecular Partners' stock price increased due to positive in vivo data for their therapy candidate MP0712, with human trials expected in 2025.
The announcement of positive in vivo data for MP0712 has likely increased investor confidence in Molecular Partners' pipeline, leading to a rise in stock price. The anticipation of human trials in 2025 further supports future growth potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100